DaVita Cash Flow from Operating Activities 2012-2026 | DVA
DaVita annual/quarterly cash flow from operating activities history and growth rate from 2012 to 2026. Cash flow from operating activities can be defined as a company's cash flows from operations.
- DaVita cash flow from operating activities for the quarter ending March 31, 2026 was $0.321B, a 84.13% decline year-over-year.
- DaVita cash flow from operating activities for the twelve months ending March 31, 2026 was $2.351B, a 41.6% decline year-over-year.
- DaVita annual cash flow from operating activities for 2025 was $1.887B, a 6.7% decline from 2024.
- DaVita annual cash flow from operating activities for 2024 was $2.022B, a 1.8% decline from 2023.
- DaVita annual cash flow from operating activities for 2023 was $2.059B, a 31.6% increase from 2022.
|
DaVita Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2025 | $1,887 |
| 2024 | $2,022 |
| 2023 | $2,059 |
| 2022 | $1,565 |
| 2021 | $1,931 |
| 2020 | $1,979 |
| 2019 | $2,072 |
| 2018 | $1,772 |
| 2017 | $1,913 |
| 2016 | $1,972 |
| 2015 | $1,557 |
| 2014 | $1,459 |
| 2013 | $1,773 |
| 2012 | $1,101 |
| 2011 | $1,180 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $10.023B | $13.643B |
| DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Quest Diagnostics (DGX) | United States | $21.197B | 19.44 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |